RT @DaveGennert: Showcasing work from @marta_chesi & @Leif_Bergsagel in @BCD_AACR on combo therapies w/ BsAb vs models of #myeloma to avoid…
Showcasing work from @marta_chesi & @Leif_Bergsagel in @BCD_AACR on combo therapies w/ BsAb vs models of #myeloma to avoid #TcellExhaustion in hi-burden disease: https://t.co/UQPbkxNhdT 2/3 #AACRbcd24 #mmsm https://t.co/8DfnzU3hHt
@HiraSMian Late reply but I stand corrected: cyclo prior to bispecifics (or in addition) may be a good thing :-) at least in a mouse model :-) https://t.co/7RXsP5DaUi
Interested in rational #myeloma #immunotherapy combinations? Check out why and how bispecifics may need #chemotherapy pretreatment for long-term response. https://t.co/1NxTpnKvRA https://t.co/EUPX7UmbRb
MMRRC #icymi publication reference update! "Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy" Jul 8, 2021 PMID: 34258584 https://t.co/ocJot4QnCm
RT @NCICancerBio: In a study funded by @theNCI Oncology Models Forum, @erinmeermeier @MayoClinic et al. developed a mouse model of #multipl…
RT @NCICancerBio: In a study funded by @theNCI Oncology Models Forum, @erinmeermeier @MayoClinic et al. developed a mouse model of #multipl…
RT @NCICancerBio: In a study funded by @theNCI Oncology Models Forum, @erinmeermeier @MayoClinic et al. developed a mouse model of #multipl…
In a study funded by @theNCI Oncology Models Forum, @erinmeermeier @MayoClinic et al. developed a mouse model of #multiplemyeloma, which showed that #IMiDs enhance the short-term efficacy of bispecific antibodies but exacerbate T-cell exhaustion @BCD_AACR
#ICYMI: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. https://t.co/tzgcvzM6n9 @MayoClinic @Leif_Bergsagel #mmsm https://t.co/ekLieCG5zO
#ICYMI: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. https://t.co/CO10qqNwsb @MayoClinic @Leif_Bergsagel #mmsm https://t.co/hUFbUBjTfP
#ICYMI: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. https://t.co/dDiGGPLne6 @MayoClinic @Leif_Bergsagel #mmsm https://t.co/C8f0iiWvdr
RT @BCD_AACR: ICYMI: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. @…
ICYMI: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. @MayoClinic @Leif_Bergsagel #mmsm https://t.co/yuhGrHqw1f https://t.co/LD7EfjRqzv
RT @RahulBanerjeeMD: Really interesting concept - as a partner drug to BCMA bispecifics in a murine model, cyclophosphamide was better than…
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
RT @RahulBanerjeeMD: Really interesting concept - as a partner drug to BCMA bispecifics in a murine model, cyclophosphamide was better than…
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
RT @RahulBanerjeeMD: Really interesting concept - as a partner drug to BCMA bispecifics in a murine model, cyclophosphamide was better than…
Really interesting concept - as a partner drug to BCMA bispecifics in a murine model, cyclophosphamide was better than pom for reasons postulated👇 needs validation in humans, but worth saying now: Cyclophosphamide = great drug or the greatest anti-myeloma
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
RT @Transplant_Doc: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overco…
Tumor burden limits bispecific antibody efficacy through T cell exhaustion in murine myeloma models. This can be overcome by concurrent cytotoxic therapy which improves T cell persistence and function @BCD_AACR #mmsm #myeloma https://t.co/oXNkbQd19d
RT @BCD_AACR: From the July issue: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotox…
New article: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy https://t.co/ZNOwqJxLCi #MMSM #MultipleMyeloma #hematology https://t.co/NQEq2srK6L
RRIDs were included in the Blood Cancer Discovery paper "Tumor Burden Limits Bispecific Antibody Efficacy t…" (https://t.co/3OGzBwZZrj). We appreciate the author's support of reproducibility. #STMpublishing #RRID
RT @Myeloma_Doc: #Myeloma Paper of the Day: Pre-clinical studies support the possibility that high tumor burden limits bispecific antibody…
RT @Myeloma_Doc: #Myeloma Paper of the Day: Pre-clinical studies support the possibility that high tumor burden limits bispecific antibody…
#Myeloma Paper of the Day: Pre-clinical studies support the possibility that high tumor burden limits bispecific antibody efficacy through T-cell exhaustion, and can be averted by concurrent cytotoxic therapy. https://t.co/q2RvJmiUfE https://t.co/1pgZTyNP1
Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy https://t.co/51LBAJNf6T https://t.co/eNxjKLnBU2
RT @PaperbirdsM: New article: Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Th…
New article: Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy https://t.co/Sl3ma4Qkqj #MMSM #MultipleMyeloma #hematology https://t.co/ALr5EFWcd2
RT @BCD_AACR: From the July issue: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotox…
From the July issue: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. https://t.co/AnQ9xKmiVz @MayoClinic @Leif_Bergsagel #mmsm https://t.co/9xJ1EFGklf
Read the article: https://t.co/D0YXGjvHOh
Read the article: https://t.co/D0YXGjvHOh
RT @BCD_AACR: Related article: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic t…
Related article: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. https://t.co/Z7a6nafpZH
RT @erinmeermeier: Excited to announce our preclinical research uncovering barriers to bispecific Ab therapy in #multiplemyeloma + drug com…
RT @DrGarethMorgan1: Important new information on how to use T cell engaging therapies #mmsm https://t.co/UBLNLqAyPT
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
RT @erinmeermeier: Excited to announce our preclinical research uncovering barriers to bispecific Ab therapy in #multiplemyeloma + drug com…
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @erinmeermeier: Excited to announce our preclinical research uncovering barriers to bispecific Ab therapy in #multiplemyeloma + drug com…
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
RT @erinmeermeier: Excited to announce our preclinical research uncovering barriers to bispecific Ab therapy in #multiplemyeloma + drug com…
RT @erinmeermeier: Excited to announce our preclinical research uncovering barriers to bispecific Ab therapy in #multiplemyeloma + drug com…
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @erinmeermeier: Excited to announce our preclinical research uncovering barriers to bispecific Ab therapy in #multiplemyeloma + drug com…
Great work indeed by @Leif_Bergsagel and Marta Chesi! Should we consider low dose cyclophosphamide in conjunction with CAR-T cell therapy?
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @DrGarethMorgan1: Important new information on how to use T cell engaging therapies #mmsm https://t.co/UBLNLqAyPT
Keep this great research coming... the future is bright for MM pts.
Important new information on how to use T cell engaging therapies #mmsm https://t.co/UBLNLqAyPT
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
RT @Rfonsi1: Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell eng…
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
Key findings by Marta Chesi Ph.D. and @Leif_Bergsagel M.D. team shows cytoreduction with cyclophosphamide enhances T cell engagers in a myeloma murine model. #mmsm @BerdejaJesus @DMadduri @AlGarfall @kenderian_ss @ninashah33 https://t.co/9z0Cb8bMBe https
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
RT @DrOlaLandgren: Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on…
Blood Cancer Discovery: Tumor burden limits bispecific antibody efficacy through T cell exhaustion in myeloma. Based on murine BCMA-CD3-targeting BsAb in the immunocompetent Vk*MYC and its IMiD-sensitive derivative Vk*MYChCRBN models of myeloma. #mmsm htt
RT @BCD_AACR: Just published #OnlineFirst: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent…
Excited to announce our preclinical research uncovering barriers to bispecific Ab therapy in #multiplemyeloma + drug combinations to help overcome them published by @BCD_AACR. Privileged to work w/ this team as my inaugural #postdoc work in Chesi & @Le
RT @BCD_AACR: Just published #OnlineFirst: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent…
Just published #OnlineFirst: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. @MayoClinic @Leif_Bergsagel #mmsm https://t.co/9py544Z0FF https://t.co/ZvO5D2Cwsh
RT @FrancescoMaura4: New COOL paper from Marta Chesi and @Leif_Bergsagel lab: Tumor burden limits bispecific antibody efficacy through T ce…
Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy | Blood Cancer Discovery https://t.co/w9IPATroqW
New COOL paper from Marta Chesi and @Leif_Bergsagel lab: Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy https://t.co/jIIbNAV3gH #mmsm #CARTcell @BCD_AACR